PRKDC and neoplasm: This requires more investigative work comparing these various radiation modalities in combination with inhibitors such as those targeting PARP, ATM, ATR, DNA-PKcs and CHK1, to confidently determine a specific strategy that is efficacious in radiosensitising specific tumours.